SAM
ARQT icon

Simplify Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Simplify Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-317,997
Closed -$5.99M – 146
2025
Q3 		$5.99M Sell
317,997
-91,435
-22% -$1.44M 0.11% 29
2025
Q2 		$5.74M Sell
409,432
-251,125
-38% -$3.52M 0.29% 23
2025
Q1 		$10.3M Sell
660,557
-81,742
-11% -$1.15M 0.39% 15
2024
Q4 		$10.3M Buy
+742,299
New +$8.13M 0.51% 14

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplify Asset Management's ARQT Position: Q4 2025 in Review

Simplify Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 317,997 shares — an estimated $5.99M sold.

Simplify Asset Management first reported a position in ARQT in Q4 2024 and held it in 4 quarters. The position peaked at $10.3M in Q4 2024. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Simplify Asset Management reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplify Asset Management sold 317,997 Arcutis Biotherapeutics shares in Q4 2025, an estimated $5.99M.
  • Simplify Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 4 quarters.
  • Simplify Asset Management's Arcutis Biotherapeutics position peaked at $10.3M in Q4 2024.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Simplify Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.